Indication: Lymphoma
An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients With Lymphoid Malignancies
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: AVM Biotechnology
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
